Evaluation of Paraoxonase, Arylesterase and Malondialdehyde Levels in Schizophrenia Patients Taking Typical, Atypical and Combined Antipsychotic Treatment

키워드

참고문헌 (32)

1. 노대영, "Antipsychotic Prescribing Patterns in First-episode Schizophrenia: A Five-year Comparison", Clinical Psychopharmacology and Neuroscience, 13(3), pp.275~282 (2015), 대한정신약물학회
2. Ganesan Venkatasubramanian, "Understanding Schizophrenia as a Disorder of Consciousness: Biological Correlates and Translational Implications from Quantum Theory Perspectives", Clinical Psychopharmacology and Neuroscience, 13(1), pp.36~47 (2015), 대한정신약물학회
3. Lan-Ting Lee, "Holistic Consideration of Patients with Schizophrenia to Improve Medication Adherence and Outcomes", Clinical Psychopharmacology and Neuroscience, 13(2), pp.138~143 (2015), 대한정신약물학회
4. 김성진, "The Relationship between Language Ability and Cognitive Function in Patients with Schizophrenia", Clinical Psychopharmacology and Neuroscience, 13(3), pp.288~295 (2015), 대한정신약물학회
5. Anupa A. Vijayakumari, "Effect of Polymorphisms of Three Genes Mediating Monoamine Signalling on Brain Morphometry in Schizophrenia and Healthy Subjects", Clinical Psychopharmacology and Neuroscience, 13(1), pp.68~82 (2015), 대한정신약물학회
6. Ganesan Venkatasubramanian, "Neuroimmunological Aberrations and Cerebral Asymmetry Abnormalities in Schizophrenia: Select Perspectives on Pathogenesis", Clinical Psychopharmacology and Neuroscience, 12(1), pp.8~18 (2014), 대한정신약물학회
7. Camkurt MA, "Comparison of plasma MicroRNA levels in drug naive, first episode depressed patients and healthy controls", J Psychiatr Res, 69, pp.67~71 (2015)
8. Hsu JW, "Association of thalamic serotonin transporter and interleukin-10 in bipolar I disorder: a SPECT study", Bipolar Disord, 16, pp.241~248 (2014)
9. Mehmet Akif Camkurt, "Investigation of Dysregulation of Several MicroRNAs in Peripheral Blood of Schizophrenia Patients", Clinical Psychopharmacology and Neuroscience, 14(3), pp.256~260 (2016), 대한정신약물학회
10. Sasi Neelamekam, "Regulation of Interleukin-6 and Leptin in Schizophrenia Patients: A Preliminary Analysis", Clinical Psychopharmacology and Neuroscience, 12(3), pp.209~214 (2014), 대한정신약물학회
11. Camkurt MA, "Evaluation of malondialdehyde, superoxide dismutase and catalase activity and their diagnostic value in drug naïve, first episode, non-smoker major depression patients and healthy controls", Psychiatr Res, 238, pp.81~85 (2016)
12. Güneş M, "Diagnostic performance of increased prolidase activity in schizophrenia", Neurosci Lett, 613, pp.36~40 (2016)
13. Gan KN, "Purification of human serum paraoxonase", arylesterase. Evidence for one esterase catalyzing both activities, 1991, pp.19, 100~106
14. Juretić D, "Serum paraoxonase activities in hemodialyzed uremic patients: cohort study", Croat Med J, 42, pp.146~150 (2001)
15. Précourt LP, "The three-gene paraoxonase family:physiologic roles, actions and regulation", Atherosclerosis, 214, pp.20~36 (2011)
16. Unsal C, "Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine", Neuropsychiatr Dis Treat, 9, pp.1545~1552 (2013)
17. Sarandol A, "Coronary artery disease risk factors in patients with schizophrenia: effects of short term antipsychotic treatment", J Psychopharmacol, 21, pp.857~863 (2007)
18. Noto C, "Oxidative stress in drug naïve first episode psychosis and antioxidant effects of risperidone", J Psychiatr Res, 68, pp.210~216 (2015)
19. Mackness MI, "Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation", Lancet, 349, pp.851~852 (1997)
20. Mackness B, "Human serum paraoxonase", Gen Pharmacol, 31, pp.329~336 (1998)
21. Herken H, "Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia", Mol Psychiatry, 6, pp.66~73 (2001)
22. Bulut M, "Malondialdehyde levels in adult attentiondeficit hyperactivity disorder", J Psychiatry Neurosci, 32, pp.435~438 (2007)
23. Grignon S, "Assessment of malondialdehyde levels in schizophrenia: a meta-analysis and some methodological considerations", Prog Neuropsychopharmacol Biol Psychiatry, 31, pp.365~369 (2007)
24. Akyol O, "The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant", antioxidant imbalance, 2002, pp.26, 995~1005
25. Eckerson HW, "The human serum paraoxonase", arylesterase polymorphism, 1983, pp.35, 1126~1138
26. Draper HH, "A comparative evaluation of thiobarbituric acid methods for the determination of malondialdehyde in biological materials", Free Radic Biol Med, 15, pp.353~363 (1993)
27. Kuloglu M, "Cinkilinc N. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder", Cell Biochem Funct, 20, pp.171~175 (2002)
28. Scottish Schizophrenia Research Group, "Smoking habits and plasma lipid peroxide and vitamin E levels in never-treated first-episode patients with schizophrenia", Br J Psychiatry, 176, pp.290~293 (2000)
29. Behl C, "Haloperidolinduced cell death--mechanism and protection with vitamin E in vitro", Neuroreport, 7, pp.360~364 (1995)
30. Park SW, "Protective effects of atypical antipsychotic drugs against MPP(+)-induced oxidative stress in PC12 cells", Neurosci Res, 69, pp.283~290 (2011)
31. Parikh V, "Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain", J Psychiatr Res, 37, pp.43~51 (2003)
32. Selek S, "Oxidative imbalance in obsessive compulsive disorder patients: a total evaluation of oxidant-antioxidant status", Prog Neuropsychopharmacol Biol Psychiatry, 32, pp.487~491 (2008)

관련 논문AI추천